Related Experiment Video
Updated: Jul 17, 2026
07:09
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Targeting P2X receptors for analgesia: Small molecule antagonists in development
Zhibin He1, Xujie Huang1, Fengchun He2
1School of Medicine, Guangxi University of Science and Technology, Liuzhou, 545005, China.
European Journal of Medicinal Chemistry
|July 15, 2026
Summary
Developing selective P2X receptor antagonists offers a promising non-opioid approach for managing chronic and neuropathic pain. Research highlights P2X3R, P2X4R, and P2X7R antagonists with demonstrated analgesic effects in preclinical models.
Area of Science:
- Pharmacology
- Neuroscience
- Medicinal Chemistry
Background:
- Chronic and neuropathic pain are difficult to manage due to limitations of current analgesics like opioids and NSAIDs.
- Purinergic signaling, particularly P2X receptors (P2XRs), plays a key role in pain processing.
- Selective P2XR antagonists represent a novel therapeutic strategy for non-opioid pain relief.
Purpose of the Study:
- To review the design and synthesis of selective small molecule antagonists for P2X3R, P2X4R, and P2X7R.
- To analyze structure-activity relationships (SAR) and in vitro data.
- To evaluate analgesic effects in preclinical rodent pain models.
Main Methods:
- Literature review of research from 2006 to 2026.
- Analysis of SAR studies for P2XR antagonists.
- Assessment of in vitro and in vivo (rodent models) efficacy data.
Main Results:
- Sivopixant (P2X3R antagonist) showed potent analgesia in a rat spinal nerve ligation model.
- NC-2600 (P2X4R antagonist) demonstrated efficacy in a rat colitis model and completed Phase I trials.
- A-740003 (P2X7R antagonist) exhibited broad-spectrum analgesic activity in neuropathic and inflammatory pain models.
Conclusions:
- Rational drug design can yield subtype-selective P2XR antagonists.
- These antagonists hold significant potential for developing novel non-opioid analgesics.
- Targeting P2XRs offers a promising avenue for effective pain management.
Related Concept Videos
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
01:22Opioid Receptors: Overview
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...